tofacitinib and Pemphigoid--Bullous

Bullous pemphigoid (BP) and psoriasis are both immune-related skin diseases. Still, the comorbidities between the two are rare, and there is no consensus on the optimal treatment strategy for BP combined with psoriasis. JAK inhibitors are emerging, molecularly targeted therapeutic agents that target the molecule of Janus kinase, a signal transducer and activator of transcription (JAK/STAT). JAK inhibitors block intracellular signaling pathways by blocking the gene transcription of key pro-inflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases. Tofacitinib is a first-generation JAK inhibitor. The purpose of this article is to describe the first report of the use of tofacitinib in treating BP combined with psoriasis vulgaris with significant results. According to our findings, tofacitinib may be a safe and effective treatment option for patients suffering from BP and psoriasis together. The implications of this are substantial for the guidance of treatment strategies for both comorbid conditions.

Topics: Humans; Janus Kinase Inhibitors; Janus Kinases; Pemphigoid, Bullous; Protein Kinase Inhibitors; Psoriasis; STAT Transcription Factors

Topics: Humans; Pemphigoid, Bullous; Piperidines; Pyrimidines

Topics: Autoantibodies; Autoantigens; Humans; Pemphigoid, Bullous; Piperidines; Prednisone; Pyrimidines